The effect of olanzapine on IGF-1 and IGF-1R in the prefrontal cortex and hypocampus in rats with a model of bipolar mania

The aim of the study is to determine the changes in insulin-like growth factor 1 (IGF-1) and its receptor (IGF-1R) in the emergence of bipolar disorder and its treatment with olanzapine. Of all 48 adult male albino wistar rats, the control group (n=12) saline (0.5 ml), ketamine group (n=12) ketamine (0.5 ml,25 mg/kg), olanzapine group (n=12) olanzapine (0.5 ml,2 mg/kg), ketamine+olanzapine group (n=12) ketamine (0.5 ml, 25 mg/kg) was administered intraperitoneally once a day for 14 days. In addition to ketamine administration, olanzapine (0.5 ml,2 mg/kg) was administered once a day to ketamine+olanzapine group between 8-14 days. Volume, IGF-1 and IGF-1R gene expression and protein levels were measured in prefrontal cortex and hippocampus. We detected that there was a decrease in volume of prefrontal cortex, IGF-1R gene expression and protein levels (immune staining) in the group in which bipolar mania model was created with ketamine; an increase in IGF-1 gene expression and protein levels (immune staining) in the olanzapine group; an increase in IGF-1R gene expression, IGF-1 and IGF-1R protein levels (immune staining) in the ketamine+olanzapine group in the prefrontal cortex. We detected that there was a decrease in volume of hippocampus, IGF-1 gene expression and protein levels in the group in which bipolar mania model was created with ketamine; a decrease in volume and IGF-1 protein levels, increase in IGF-1R gene expression and protein levels (immune staining) in the olanzapine group; a decrease in volume, IGF-1 protein levels and IGF-1R gene expression and protein levels in the ketamine+olanzapine group in the hippocampus. We detected that there was a decrease in volume of prefrontal cortex, IGF-1R gene expression and protein levels (immune staining) in the group in which bipolar mania model was created with ketamine; an increase in IGF-1 gene expression and protein levels (immune staining) in the olanzapine group; an increase in IGF-1R gene expression, IGF-1 and IGF-1R protein levels (immune staining) in the ketamine+olanzapine group in the prefrontal cortex. We detected that there was a decrease in volume of hippocampus, IGF-1 gene expression and protein levels in the group in which bipolar mania model was created with ketamine; a decrease in volume and IGF-1 protein levels, increase in IGF-1R gene expression and protein levels (immune staining) in the olanzapine group; a decrease in volume, IGF-1 protein levels and IGF-1R gene expression and protein levels in the ketamine+olanzapine group in the hippocampus.